Levothyroxine Sodium Tablets Recalled Due to Potency Failures
Viatris Inc is recalling Levothyroxine Sodium Tablets USP, 137 mcg due to potency failures in some tablets being stronger or weaker than specified. The recall affects 118,324 bottles distributed nationwide in the United States and Puerto Rico.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for potency failures with no reported illnesses or injuries. Per the rubric, risk-of-harm products where injury has not yet been reported are classified as High (3).
Plain-English summary
Viatris Inc is recalling Levothyroxine Sodium Tablets USP, 137 mcg in both 90-count and 1000-count bottles. The affected products span six lot numbers with expiration dates ranging from December 2024 to September 2025. A total of 118,324 bottles have been distributed nationwide within the United States and Puerto Rico.
The recall was initiated due to potency failures identified in the tablets. Testing confirmed that some tablets are superpotent (containing higher-than-specified potency) while others are subpotent (containing lower-than-specified potency). This variability in drug strength could affect the consistent treatment of thyroid conditions for patients who depend on precise dosing.
Patients taking Levothyroxine Sodium Tablets from the affected lot numbers should contact their healthcare provider or pharmacy immediately. Consumers should not stop taking their medication without medical guidance, as abruptly discontinuing levothyroxine can be harmful. Healthcare providers can advise patients on whether to continue using their current supply or switch to an alternative source of levothyroxine.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Viatris Inc
- Category
- Drug — Thyroid Medication
- Hazard
- potency-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot #: a) 8165919
- Exp. Date Dec 2024
- 8172050
- Exp. Date Mar 2025
- 8183251
- Exp. Date Sept 2025 b) 3185542
- Exp. date Dec 2024
- 3192838
- 3208172
- Exp. Date Sept 2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighLevothyroxine Sodium Tablets Recalled for Out-of-Specification Potency
FDA (Drugs) · 2025-03-26
- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium tablets recalled for impurity specification failure
FDA (Drugs) · 2025-01-08
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
- HighFDA Recalls Levothyroxine Sodium Tablets for Potency Variation
FDA (Drugs) · 2024-12-18
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27